Efficacy subgroups: baseline demographics and reasons for discontinuation
multiple sclerosis disease, RRMS
RELAPSING REMITTING MULTIPLE SCLEROSIS, MULTIPLE SCLEROSIS, SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
The efficacy analysis set included 1882 patients: in ASCLEPIOS I/II, 936 and 946 patients were randomized to teriflunomide and ofatumumab, respectively; 72.6% (Baseline demographics and clinical characteristics (efficacy analysis setBMI: body mass index; EDSS: Expanded Disability Status Scale; Gd+: gadolinium-enhancing; MS: multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SD: standard deviation; SPMS: secondary progressive multiple sclerosis.Data from the efficacy analysis set.Patients who completed treatment with teriflunomide in the core period were switched to ofatumumab in the open-label extension period.Treatment-naive patients had not received a prior multiple sclerosis disease modifying therapy.Not applicable, as all patients had previously received teriflunomide.Values at the baseline of the open-label extension period in the newly switched ofatumumab group reflect the teriflunomide treatment effect during the core period.